Immix Biopharma (NASDAQ:IMMX) Shares Climb 5.8% – Should You Buy?

Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) shares traded up 5.8% during trading on Friday. The stock traded as high as $7.46 and last traded at $7.4490. Approximately 204,967 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 1,305,224 shares. The stock had previously closed at $7.04.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Mizuho dropped their price objective on Immix Biopharma from $23.00 to $22.00 and set an “outperform” rating on the stock in a report on Wednesday. HC Wainwright upped their target price on shares of Immix Biopharma from $25.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday, November 16th. Citigroup reaffirmed a “market outperform” rating on shares of Immix Biopharma in a research note on Wednesday, September 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a report on Thursday, October 15th. Finally, Needham & Company LLC raised their price target on Immix Biopharma from $21.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, September 29th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.14.

Check Out Our Latest Report on Immix Biopharma

Immix Biopharma Trading Down 1.1%

The company has a market capitalization of $583.32 million, a PE ratio of -8.39 and a beta of 0.29. The business’s 50-day simple moving average is $9.25 and its two-hundred day simple moving average is $9.61.

Immix Biopharma (NASDAQ:IMMX – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19). On average, analysts forecast that Immix Biopharma, Inc. will post -0.75 EPS for the current year.

Institutional Trading of Immix Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of IMMX. Jupiter Topco LLC bought a new stake in Immix Biopharma during the second quarter worth approximately $100,816,000. Janus Henderson Group PLC lifted its position in shares of Immix Biopharma by 22.5% in the first quarter. Janus Henderson Group PLC now owns 4,802,002 shares of the company’s stock worth $43,698,000 after buying an additional 880,434 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Immix Biopharma during the 2nd quarter worth $30,827,000. Opaleye Management Inc. bought a new position in Immix Biopharma in the 2nd quarter worth approximately $24,177,000. Finally, Marshall Wace LLP lifted its stake in shares of Immix Biopharma by 3.3% in the third quarter. Marshall Wace LLP now owns 1,854,215 shares of the company’s stock valued at $19,284,000 after buying an additional 59,307 shares during the period. Institutional investors own 11.26% of the company’s stock.

About Immix Biopharma

(Get Free Report)

Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies for serious diseases, with a focus on relapsed or refractory AL amyloidosis, a rare condition in which abnormal proteins build up in organs and tissues. The company’s lead candidate, NXC-201, is an investigational CAR T-cell therapy designed to target BCMA, a protein found on certain plasma cells. It is being studied in clinical trials and has not been approved for commercial use. Immix Biopharma is based in the United States and is led by Chief Executive Officer Ilya Rachman.

Further Reading

Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.